Clinical trials · Michigan
Locally Advanced Breast Cancer clinical trials in Michigan
We’re tracking 71 recruiting locally advanced breast cancer studies with a site in Michigan — including Phase 1, Phase 1/Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Michigan
- NCT06827236RecruitingPhase 1/Phase 2
Testing a new combination treatment for advanced breast cancer
This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.
Detroit, MichiganAges 18 years+ - NCT06590857RecruitingPhase 1/Phase 2
Study of targeted radiation for advanced breast cancer
This trial tests a new type of radiation therapy that targets a specific protein on some breast cancer cells. It may help people whose cancer has stopped responding to other treatments.
Detroit, MichiganAges Any age - NCT07492641RecruitingPhase 3
A new drug plus letrozole for advanced HR+ breast cancer
This trial tests a new medicine (BGB-43395) combined with letrozole against the usual CDK4/6 inhibitor plus letrozole. It is for people with advanced or metastatic HR-positive, HER2-negative breast cancer who have not yet had treatment for advanced disease.
Detroit, MichiganAges 18 years+ - NCT07357597RecruitingPhase 4
Preventing mouth sores during breast or lung cancer treatment
This trial tests whether a steroid mouthwash can prevent mouth sores caused by the drug Datopotamab Deruxtecan (Dato-DXd). It is for people with certain types of advanced breast cancer or lung cancer who are about to start Dato-DXd for the first time.
Grayling, MichiganAges 18 years+ - NCT07310420RecruitingPhase 1
Evaluating ovarian suppression with ZOLADEX in premenopausal breast cancer
This trial tests a medication (ZOLADEX) to suppress ovarian function in premenopausal women with hormone receptor-positive breast cancer, either early-stage or advanced. The goal is to see how well it works and how safe it is.
Royal Oak, MichiganAges 18–55 - NCT07227831Recruiting
TheraBionic device for advanced hormone-positive breast cancer
This trial tests a device called TheraBionic P1, which uses low-level radiofrequency energy to treat advanced breast cancer that has stopped responding to standard treatments. It may offer a new option for people who have exhausted other therapies.
Flint, MichiganAges 22 years+ - NCT07189871RecruitingPhase 1/Phase 2
Targeted radiation therapy for advanced solid tumors
This study tests a new radioactive treatment (177Lu-BetaBart) for people with certain advanced solid tumors that have stopped responding to standard treatments. It aims to see if this targeted therapy can slow or stop tumor growth.
Grand Rapids, MichiganAges 18 years+ - NCT07174336RecruitingPhase 3
Testing Tersolisib with other treatments for advanced breast cancer
This trial tests a new study drug called Tersolisib combined with other anti-cancer treatments for people with advanced breast cancer that has a specific gene change (PIK3CA). The goal is to see if the combination can help shrink or slow the cancer.
Sterling Heights, MichiganAges 18 years+ - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
Grand Rapids, MichiganAges 18 years+ - NCT07085767RecruitingPhase 3
Palazestrant and ribociclib for first-line advanced breast cancer
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
Ann Arbor, MichiganAges 18 years+ - NCT07062965RecruitingPhase 3
PF-07248144 with fulvestrant for HR+ HER2- advanced breast cancer
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Holland, MichiganAges 18 years+ - NCT07029399RecruitingPhase 1
Study of NKT5097 for advanced solid tumors
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT06982521RecruitingPhase 3
Comparing two drug combinations for advanced breast cancer
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
Ann Arbor, MichiganAges 18 years+ - NCT06958328RecruitingPhase 3
Higher dose radiation for locally advanced pancreatic cancer
This trial tests whether giving a higher dose of radiation to the pancreas is safe and effective for people with locally advanced pancreatic cancer who have already had chemotherapy without progression.
Brighton, MichiganAges 18 years+ - NCT06866262RecruitingPhase 1/Phase 2
Inulin gel with immunotherapy for advanced kidney cancer
This trial tests whether adding an inulin gel to standard immunotherapy (ipilimumab and nivolumab) can help treat kidney cancer that has spread or cannot be removed. It is for people who have not had prior treatment for advanced disease.
Ann Arbor, MichiganAges 18 years+ - NCT06840886RecruitingPhase 1
Study of PHST001 for advanced solid tumors
This trial tests an experimental drug called PHST001 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if PHST001 can help shrink or control the tumor.
Ann Arbor, MichiganAges 18 years+ - NCT06799065RecruitingPhase 1/Phase 2
Oral drug for advanced solid tumors including ovarian cancer
This trial tests a new daily pill that targets a protein helping cancer cells divide. It may stop tumors from growing in people with advanced or metastatic cancer that has returned or stopped responding to standard treatments, including some types of ovarian, lung, and other solid tumors.
Detroit, MichiganAges 18 years+ - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Detroit, MichiganAges 18 years+ - NCT06757634RecruitingPhase 3
A study of gedatolisib for first-line advanced breast cancer
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
Detroit, MichiganAges 18 years+ - NCT06562192RecruitingPhase 1
Testing a radioactive drug for advanced pancreatic, lung, breast, and colorectal cancers
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
Grand Rapids, MichiganAges 18–100 - NCT06524544RecruitingPhase 3
Pembrolizumab and sacituzumab govitecan for advanced bladder cancer
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
Brighton, MichiganAges 18 years+ - NCT06380751RecruitingPhase 3
New targeted therapy for BRCA/PALB2-mutated HR+ breast cancer
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
Dearborn, MichiganAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Ann Arbor, MichiganAges 18 years+ - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Detroit, MichiganAges 18 years+
Where these studies are running in Michigan
Institutions with a site for the recruiting locally advanced breast cancer studies listed above.
- Henry Ford Health · 4 studies
- Karmanos Cancer Institute · 4 studies
- BAMF Health · 2 studies
- Profound Research LLC · 2 studies
- Research Site · 2 studies
- START Midwest · 2 studies
- Trinity Health Brighton · 2 studies
- Trinity Health IHA Medical Group Hematology Oncology - Canton · 2 studies
What taking part in a locally advanced breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Locally Advanced Breast Cancer trials in other states
Common questions
- Are there locally advanced breast cancer clinical trials in Michigan?
- Yes. We're currently tracking 71 recruiting locally advanced breast cancer studies with a site in Michigan, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a locally advanced breast cancer study in Michigan?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Michigan to take part?
- Not necessarily. These studies have a site in Michigan, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a locally advanced breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New locally advanced breast cancer studies open in Michigan regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.